Cardio-Oncology and Breast Cancer Therapies
- PMID: 40257669
- DOI: 10.1007/s11864-025-01311-x
Cardio-Oncology and Breast Cancer Therapies
Abstract
Assessing cardiac risk prior to initiating breast cancer treatment, monitoring cardiac function during treatment, and implementing appropriate follow-up strategies are essential components of managing cardiotoxicity in breast cancer patients. A comprehensive cardiovascular evaluation should be conducted before treatment, including a detailed medical history, physical examination, and baseline cardiac imaging. Risk stratification tools can aid in determining the individual patient's risk profile. Close monitoring of cardiac function, including regular assessment of left ventricular ejection fraction (LVEF) and monitoring for signs and symptoms of cardiac dysfunction, is crucial during treatment. Prompt action should be taken if an adverse cardiovascular event is detected, including considering discontinuing or modifying the treatment regimen. Appropriate follow-up care is essential to monitor for long-term cardiac effects and optimize cardiovascular health in breast cancer survivors. Regular cardiovascular assessments, lifestyle modifications, and collaboration between healthcare professionals are important in managing cardiotoxicity effectively.
Keywords: Breast cancer; Cardio-oncology; Cardiotoxicity.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests. Human and Animal Rights and Informed Consent: This article does not contain any studies with human or animal subjects performed by any of the authors.
Similar articles
-
Cardiotoxicity of Contemporary Breast Cancer Treatments.Curr Treat Options Oncol. 2019 May 9;20(6):51. doi: 10.1007/s11864-019-0646-1. Curr Treat Options Oncol. 2019. PMID: 31073788 Free PMC article. Review.
-
Exercise-based cardio-oncology rehabilitation for cardiotoxicity prevention during breast cancer chemotherapy: The ONCORE randomized controlled trial.Prog Cardiovasc Dis. 2024 Jul-Aug;85:74-81. doi: 10.1016/j.pcad.2024.02.002. Epub 2024 Feb 21. Prog Cardiovasc Dis. 2024. PMID: 38395212 Clinical Trial.
-
Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies : Position paper of the Heart Failure Working Group of the Austrian Society of Cardiology.Wien Klin Wochenschr. 2022 Sep;134(17-18):654-674. doi: 10.1007/s00508-022-02031-0. Epub 2022 May 4. Wien Klin Wochenschr. 2022. PMID: 35507087 Free PMC article.
-
[The Cardio-Oncology Guideline - A Comprehensive Approach to Managing Cardiovascular Risks in Cancer Patients].Dtsch Med Wochenschr. 2024 Jun;149(12):719-723. doi: 10.1055/a-2104-6363. Epub 2024 May 23. Dtsch Med Wochenschr. 2024. PMID: 38781996 Review. German.
-
Understanding cardiac events in breast cancer (UCARE): pilot cardio-oncology assessment and surveillance pathway for breast cancer patients.Breast Cancer Res Treat. 2024 Sep;207(2):283-291. doi: 10.1007/s10549-024-07322-w. Epub 2024 Jun 26. Breast Cancer Res Treat. 2024. PMID: 38922547 Free PMC article.
References
References and Recommended Reading
-
- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Circulation. Accessed June 18, 2024. https://www.ahajournals.org/doi/ https://doi.org/10.1161/CIR.0000000000001063
-
- Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229–361. https://doi.org/10.1093/eurheartj/ehac244 . - DOI - PubMed
-
- Cardinale D, Colombo A, Bacchiani G, et al. Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy. Circulation. 2015;131(22):1981–8. https://doi.org/10.1161/CIRCULATIONAHA.114.013777 . - DOI - PubMed
-
- Michel L, Mincu RI, Mahabadi AA, et al. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. Eur J Heart Fail. 2020;22(2):350–61. https://doi.org/10.1002/ejhf.1631 . - DOI - PubMed
-
- Romann SW, Giannitsis E, Frey N, Lehmann LH. Troponin Elevation in Asymptomatic Cancer Patients: Unveiling Connections and Clinical Implications. Curr Heart Fail Rep. 2024;21(6):505–14. https://doi.org/10.1007/s11897-024-00681-x . - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical